METHODS: Demographic, clinical, and management data of patients with lung LCNEC were extracted from the SEER database for the period 2000-2018.
RESULTS: In the USA, LCNEC has a higher incidence in elderly white men: M:F ratio = 1.2:1, Caucasian: 83.3%, mean age: 67 ± 10.2 years. The most common treatment modality was chemotherapy only: 29.2%, followed by surgery: 21.5% (but in this group the statuses of chemotherapy were unknown), and combination surgery/chemotherapy: 8.8%. The overall and cause-specific 5-year survival was 17.5% (95% CI 16.3-18.8) and 21.9% (95% CI 20.5-23.4), respectively. By treatment, the best 5-year survival was for surgery alone (48%), followed by multimodality therapy (chemo + surgery + radiation) at 35% (95% CI 27-43). Age > 60 years, male gender, size > 7 cm, and nodal and liver metastasis were independent risk factors associated with increased mortality.
CONCLUSIONS: Lung LCNEC is an aggressive neoplasm most common in older white males that presents at an advanced stage despite small primary tumors. Most patients die within 2 years. The best predictor of survival is surgery with chemotherapy. Given its dismal prognosis, new treatment guidelines are needed for this aggressive cancer.
方法:人口统计学,临床,我们从SEER数据库中提取了2000-2018年肺部LCNEC患者的管理数据.
结果:在美国,LCNEC在老年白人男性中的发病率较高:M:F比率=1.2:1,白种人:83.3%,平均年龄:67±10.2岁。最常见的治疗方式仅是化疗:29.2%,其次是手术:21.5%(但该组的化疗状态未知),联合手术/化疗:8.8%。总体和病因特异性5年生存率分别为17.5%(95%CI16.3-18.8)和21.9%(95%CI20.5-23.4),分别。通过治疗,最好的5年生存率是单独手术(48%),其次是多模式治疗(化疗+手术+放疗),占35%(95%CI27-43)。年龄>60岁,男性,尺寸>7厘米,淋巴结转移和肝转移是增加死亡率的独立危险因素。
结论:肺LCNEC是一种侵袭性肿瘤,最常见于老年白人男性,尽管原发性肿瘤较小,但仍处于晚期。大多数患者在2年内死亡。生存的最佳预测指标是手术加化疗。鉴于其令人沮丧的预后,这种侵袭性癌症需要新的治疗指南.